QuiaPEG

Newsroom

Sept 13, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) today announced that a patent application has been filed with the U.S. Patent Office. If the application is subsequently granted, QuiaPEG will obtain a patent protection to at least the end of 2038.

QuiaPEG received initial results in a development project earlier this year, in collaboration with a global medium-sized pharmaceutical company, which has provided an active drug substance, a so-called biosimilar, ie a copy of an existing biological drug. The pre-clinical development work has yielded positive results now underlying the above-mentioned patent application.

For reasons of competition, the identities of the international pharmaceutical company and the original drug, as well as the results are confidential.

Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message